Amyotrophic lateral sclerosis diagnostic study of choice

Jump to navigation Jump to search

Amyotrophic lateral sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Amyotrophic lateral sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Amyotrophic lateral sclerosis diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Amyotrophic lateral sclerosis diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Amyotrophic lateral sclerosis diagnostic study of choice

CDC on Amyotrophic lateral sclerosis diagnostic study of choice

Amyotrophic lateral sclerosis diagnostic study of choice in the news

Blogs on Amyotrophic lateral sclerosis diagnostic study of choice

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Amyotrophic lateral sclerosis diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

ALS is a clinical diagnosis. Due to the absence of any disease bio-markers, the presence of both UMN and LMN signs and symptoms in the same body region along with the progression of these symptoms. Modified El-Escorial diagnostic criteria are used for elucidation of electrophysiological changes for the diagnosis of ALS. El- Escorial criteria are also known as Airlie House recommendations. It was revised in a meeting at Awaji Island, Japan in 2006. Current Airlie house recommendations were revised step by step. Awaji criteria have a significant impact on the early diagnosis of ALS. Currently, Gold coast criteria are used for the diagnosis of ALS.

Diagnostic Study of Choice

Name of Diagnostic Criteria

  • Awaji Criteria for the diagnosis of ALS was proposed to facilitate the diagnosis of ALS in the early stage.

Major points include:

  • Electromyography is considered equivalent to the clinical examination of the identification for LMN signs and fasciculations.

[1]

  • Both Awaji and El-escorial criteria are complicated to apply for the diagnosis of ALS and also prone to errors.
  • For all these reasons 'Gold coast criteria were established to modify the existing criteria and to simplify the diagnosis of ALS.

Key points of Gold coast criteria are:

1. Progressive motor degeneration documented by history/repeated clinical evaluation, with previously normal motor function, and

2. Presence of upper and lower motor neuron dysfunction in at least one body region, (with upper and lower motor neuron dysfunction noted in the same body region) or lower motor neuron dysfunction in at least two body regions, and

3. Key Investigations (EMG, imaging, etc) that exclude other disease processes.

[2]

References

  1. Guennoc AM, Camu W, Corcia P (2013). "[Awaji criteria: new diagnostic criteria for amyotrophic lateral sclerosis]". Rev Neurol (Paris). 169 (6–7): 470–5. doi:10.1016/j.neurol.2012.10.007. PMID 23261262.
  2. Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A; et al. (2020). "A proposal for new diagnostic criteria for ALS". Clin Neurophysiol. 131 (8): 1975–1978. doi:10.1016/j.clinph.2020.04.005. PMID 32387049 Check |pmid= value (help).

Template:WH Template:WS